Literature DB >> 23102585

Innovative financing for health: what is truly innovative?

Rifat Atun1, Felicia Marie Knaul, Yoko Akachi, Julio Frenk.   

Abstract

Development assistance for health has increased every year between 2000 and 2010, particularly for HIV/AIDS, tuberculosis, and malaria, to reach US$26·66 billion in 2010. The continued global economic crisis means that increased external financing from traditional donors is unlikely in the near term. Hence, new funding has to be sought from innovative financing sources to sustain the gains made in global health, to achieve the health Millennium Development Goals, and to address the emerging burden from non-communicable diseases. We use the value chain approach to conceptualise innovative financing. With this framework, we identify three integrated innovative financing mechanisms-GAVI, Global Fund, and UNITAID-that have reached a global scale. These three financing mechanisms have innovated along each step of the innovative finance value chain-namely resource mobilisation, pooling, channelling, resource allocation, and implementation-and integrated these steps to channel large amounts of funding rapidly to low-income and middle-income countries to address HIV/AIDS, malaria, tuberculosis, and vaccine-preventable diseases. However, resources mobilised from international innovative financing sources are relatively modest compared with donor assistance from traditional sources. Instead, the real innovation has been establishment of new organisational forms as integrated financing mechanisms that link elements of the financing value chain to more effectively and efficiently mobilise, pool, allocate, and channel financial resources to low-income and middle-income countries and to create incentives to improve implementation and performance of national programmes. These mechanisms provide platforms for health funding in the future, especially as efforts to grow innovative financing have faltered. The lessons learnt from these mechanisms can be used to develop and expand innovative financing from international sources to address health needs in low-income and middle-income countries.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23102585     DOI: 10.1016/S0140-6736(12)61460-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  20 in total

1.  Scientific challenges and opportunities in developing novel vaccines for the emerging and developing markets: New Technologies in Emerging Markets, October 16th-18th 2012, World Vaccine Congress, Lyon.

Authors:  Sonali Kochhar
Journal:  Hum Vaccin Immunother       Date:  2013-01-15       Impact factor: 3.452

2.  Global response to HIV: treatment as prevention, or treatment for treatment?

Authors:  Kim C E Sigaloff; Joep M A Lange; Julio Montaner
Journal:  Clin Infect Dis       Date:  2014-07       Impact factor: 9.079

3.  Gut Health in the era of the human gut microbiota: from metaphor to biovalue.

Authors:  Vincent Baty; Bruno Mougin; Catherine Dekeuwer; Gérard Carret
Journal:  Med Health Care Philos       Date:  2014-11

Review 4.  The Lancet Commission on diagnostics: transforming access to diagnostics.

Authors:  Kenneth A Fleming; Susan Horton; Michael L Wilson; Rifat Atun; Kristen DeStigter; John Flanigan; Shahin Sayed; Pierrick Adam; Bertha Aguilar; Savvas Andronikou; Catharina Boehme; William Cherniak; Annie Ny Cheung; Bernice Dahn; Lluis Donoso-Bach; Tania Douglas; Patricia Garcia; Sarwat Hussain; Hari S Iyer; Mikashmi Kohli; Alain B Labrique; Lai-Meng Looi; John G Meara; John Nkengasong; Madhukar Pai; Kara-Lee Pool; Kaushik Ramaiya; Lee Schroeder; Devanshi Shah; Richard Sullivan; Bien-Soo Tan; Kamini Walia
Journal:  Lancet       Date:  2021-10-06       Impact factor: 79.321

5.  Who should pay for global health, and how much?

Authors:  Luis R Carrasco; Richard Coker; Alex R Cook
Journal:  PLoS Med       Date:  2013-02-19       Impact factor: 11.069

6.  Financing essential HIV services: a new economic agenda.

Authors:  Anna Vassall; Michelle Remme; Charlotte Watts; Timothy Hallett; Mariana Siapka; Peter Vickerman; Fern Terris-Prestholt; Markus Haacker; Lori Heise; Andy Haines; Rifat Atun; Peter Piot
Journal:  PLoS Med       Date:  2013-12-17       Impact factor: 11.069

7.  The unfolding counter-transition in rural South Africa: mortality and cause of death, 1994-2009.

Authors:  Brian Houle; Samuel J Clark; F Xavier Gómez-Olivé; Kathleen Kahn; Stephen M Tollman
Journal:  PLoS One       Date:  2014-06-24       Impact factor: 3.240

Review 8.  Medical imaging and nuclear medicine: a Lancet Oncology Commission.

Authors:  Hedvig Hricak; May Abdel-Wahab; Rifat Atun; Miriam Mikhail Lette; Diana Paez; James A Brink; Lluís Donoso-Bach; Guy Frija; Monika Hierath; Ola Holmberg; Pek-Lan Khong; Jason S Lewis; Geraldine McGinty; Wim J G Oyen; Lawrence N Shulman; Zachary J Ward; Andrew M Scott
Journal:  Lancet Oncol       Date:  2021-03-04       Impact factor: 41.316

9.  Impact of Noncommunicable Disease Multimorbidity on Healthcare Utilisation and Out-Of-Pocket Expenditures in Middle-Income Countries: Cross Sectional Analysis.

Authors:  John Tayu Lee; Fozia Hamid; Sanghamitra Pati; Rifat Atun; Christopher Millett
Journal:  PLoS One       Date:  2015-07-08       Impact factor: 3.240

10.  Funding infectious disease research: a systematic analysis of UK research investments by funders 1997-2010.

Authors:  Joseph R Fitchett; Michael G Head; Mary K Cooke; Fatima B Wurie; Rifat Atun
Journal:  PLoS One       Date:  2014-08-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.